Table 1. Biologics for the treatment of atopic dermatitis in clinical trials.

Agent	Mechanism	Trial Phase
Lebrikizumab	Anti-IL-13 mAb	Phase 3
Nemolizumab	Anti-IL-31RA mAb	Phase 3
GBR830	Anti-OX40 mAb	Phase 2
KY1005	Anti-OX40 mAb	Phase 2
Tezepelumab	Anti-TSLP mAb	Phase 2
ANB020/Etokimab	Anti-IL-33 mAb	Phase 2, early terminated
PF-06817024	Anti-IL-33 mAb	Phase 1
Fezakinumab	Anti-IL-22 mAb	Phase 2
Bermekimab	Anti-IL-1α mAb	Phase 2